Naslov
The interplay of lung cancer, COVID-19, and vaccines

Autori
Trivanović, Dragan ; Peršurić, Željka ; Agaj, Andrea ; Jakopović, Marko ; Samaržija, Miroslav ; Bitar, Lela ; Pavelić, Krešimir

Izvornik
International journal of molecular sciences (1422-0067) 23 (2022), 23; 15067, 15

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
COVID-19 ; vaccine ; solid cancers ; lung cancer ; immune checkpoint inhibitors

Sažetak
Patients with cancer are more susceptible to a higher risk of coronavirus infection and its severe complications than the general population. In addition, these patients were not included in the pivotal clinical trials for COVID-19 vaccines. Therefore, considerable uncertainty remains regarding the management of cancer patients during the COVID-19 pandemic and the safety of COVID-19 vaccinations in cancer patients. In this review, we summarize the current knowledge generated from the beginning of the COVID-19 pandemic on the vulnerability of cancer patients to the coronavirus disease, as well as the effectiveness of COVID-19 vaccines in this population. We also discuss the available data on the effects of anticancer treatment with immune checkpoint inhibitors on the immune responses to SARS-CoV-2 in cancer patients. Special attention in this review will be given to patients with lung cancer, as such patients are at an increased risk for severe effects from COVID-19.

Izvorni jezik
Engleski

Napomena
Patients with cancer are more susceptible to a
higher risk of coronavirus infection and its
severe complications than the general population.
In addition, these patients were not included in
the pivotal clinical trials for COVID-19 vaccines.
Therefore, considerable uncertainty remains
regarding the management of cancer patients during
the COVID-19 pandemic and the safety of COVID-19
vaccinations in cancer patients. In this review,
we summarize the current knowledge generated from
the beginning of the COVID-19 pandemic on the
vulnerability of cancer patients to the
coronavirus disease, as well as the effectiveness
of COVID-19 vaccines in this population. We also
discuss the available data on the effects of
anticancer treatment with immune checkpoint
inhibitors on the immune responses to SARS-CoV-2
in cancer patients. Special attention in this
review will be given to patients with lung cancer,
as such patients are at an increased risk for
severe effects from COVID-19.

POVEZANOST RADA